BioAtla (BCAB) Competitors $0.72 -0.06 (-7.34%) As of 11:42 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCAB vs. PLX, BHST, IKT, SKYE, TARA, SPRO, CRBP, PYXS, FATE, and BMEAShould you be buying BioAtla stock or one of its competitors? The main competitors of BioAtla include Protalix BioTherapeutics (PLX), BioHarvest Sciences (BHST), Inhibikase Therapeutics (IKT), Skye Bioscience (SKYE), Protara Therapeutics (TARA), Spero Therapeutics (SPRO), Corbus Pharmaceuticals (CRBP), Pyxis Oncology (PYXS), Fate Therapeutics (FATE), and Biomea Fusion (BMEA). These companies are all part of the "pharmaceutical products" industry. BioAtla vs. Its Competitors Protalix BioTherapeutics BioHarvest Sciences Inhibikase Therapeutics Skye Bioscience Protara Therapeutics Spero Therapeutics Corbus Pharmaceuticals Pyxis Oncology Fate Therapeutics Biomea Fusion Protalix BioTherapeutics (NYSE:PLX) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk. Do analysts rate PLX or BCAB? Protalix BioTherapeutics presently has a consensus price target of $15.00, indicating a potential upside of 700.00%. BioAtla has a consensus price target of $5.00, indicating a potential upside of 596.38%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Protalix BioTherapeutics is more favorable than BioAtla.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00BioAtla 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk and volatility, PLX or BCAB? Protalix BioTherapeutics has a beta of -0.23, indicating that its share price is 123% less volatile than the S&P 500. Comparatively, BioAtla has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Does the media refer more to PLX or BCAB? In the previous week, Protalix BioTherapeutics and Protalix BioTherapeutics both had 1 articles in the media. Protalix BioTherapeutics' average media sentiment score of 0.78 beat BioAtla's score of 0.64 indicating that Protalix BioTherapeutics is being referred to more favorably in the media. Company Overall Sentiment Protalix BioTherapeutics Positive BioAtla Positive Is PLX or BCAB more profitable? BioAtla has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat BioAtla's return on equity.Company Net Margins Return on Equity Return on Assets Protalix BioTherapeutics-21.03% -30.89% -11.74% BioAtla N/A -1,177.18%-137.51% Which has better valuation and earnings, PLX or BCAB? Protalix BioTherapeutics has higher revenue and earnings than BioAtla. BioAtla is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtalix BioTherapeutics$61.95M2.41$8.31M$0.0726.79BioAtla$11M3.83-$69.78M-$1.10-0.65 Do institutionals and insiders have more ownership in PLX or BCAB? 16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 6.5% of Protalix BioTherapeutics shares are held by company insiders. Comparatively, 11.2% of BioAtla shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryProtalix BioTherapeutics beats BioAtla on 9 of the 15 factors compared between the two stocks. Get BioAtla News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAB vs. The Competition Export to ExcelMetricBioAtlaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.46M$3.12B$5.74B$10.27BDividend YieldN/A2.32%5.73%4.60%P/E Ratio-0.6421.3675.3126.23Price / Sales3.83249.18459.1990.15Price / CashN/A44.4425.8129.91Price / Book2.879.5313.006.26Net Income-$69.78M-$53.20M$3.29B$270.67M7 Day Performance17.47%0.26%0.95%2.93%1 Month Performance95.27%4.11%4.81%6.12%1 Year Performance-60.33%9.03%71.37%26.03% BioAtla Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCABBioAtla2.3461 of 5 stars$0.72-7.3%$5.00+596.4%-57.2%$41.46M$11M-0.6460PLXProtalix BioTherapeutics2.3225 of 5 stars$1.58+2.6%$15.00+849.4%+72.4%$125.98M$61.95M-12.15200Positive NewsHigh Trading VolumeBHSTBioHarvest Sciences2.4325 of 5 stars$7.14-5.9%$13.67+91.4%N/A$124.67M$25.19M-10.20N/AGap UpIKTInhibikase Therapeutics0.0063 of 5 stars$1.66-0.6%N/AN/A$124.44M$260K0.006SKYESkye Bioscience2.0611 of 5 stars$4.12+3.0%$15.50+276.2%-29.2%$123.95MN/A-3.8911Gap UpTARAProtara Therapeutics1.7367 of 5 stars$3.07-2.5%$19.60+538.4%+67.0%$121.53MN/A-1.9030Positive NewsSPROSpero Therapeutics4.386 of 5 stars$2.00-7.0%$5.00+150.0%+38.7%$120.99M$47.98M-2.04150News CoveragePositive NewsShort Interest ↓CRBPCorbus Pharmaceuticals4.3203 of 5 stars$9.89+0.3%$49.00+395.4%-83.0%$120.84MN/A-2.0840Positive NewsPYXSPyxis Oncology2.6971 of 5 stars$1.96+2.6%$7.75+295.4%-51.9%$118.46M$16.15M-1.2260Gap UpHigh Trading VolumeFATEFate Therapeutics3.985 of 5 stars$0.97-4.4%$3.30+241.6%-76.0%$116.48M$13.63M-0.67550Positive NewsBMEABiomea Fusion3.4184 of 5 stars$1.81-5.7%$14.80+717.7%-75.4%$114.26MN/A-0.6050Positive News Related Companies and Tools Related Companies PLX Alternatives BHST Alternatives IKT Alternatives SKYE Alternatives TARA Alternatives SPRO Alternatives CRBP Alternatives PYXS Alternatives FATE Alternatives BMEA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAB) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAtla With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCAB Stock Alerts